| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to medicine and can be used for the introduction of an anti-coagulating system to a subject requiring it, where the anti-coagulating system includes an aptamer, binding IX/IXa factor, and an aptamer-binding antidote. For this purpose carried out are: a) measurement of the subject's weight in kilograms; b) introduction to the subject of an aptamer dose, effective for the achievement of coagulation inhibition in the subject, where the aptamer includes sequence SEQ ID No:1 and where the aptamer dose constitutes from 0.1 mg/kg to 2.0 mg/kg or from 5 mg/kg to 10 mg/kg; and c) introduction of the aptamer antidote dose to the subject, where the antidote includes sequence SEQ ID No:2, and the antidote dose is based only on the wt/wt ratio with the aptamer dose, and where the wt/wt ratio of the aptamer dose with the antidote dose constitutes from approximately 0.1:1 to approximately 20:1, and where the subject is subjected to procedures of re-vascularisation of peripheral vessels.EFFECT: neutralisation of the aptamer activity to a desirable degree is provided, with the antidote dose being fully based on its connection with the aptamer dose.17 cl, 24 dwg, 7 tbl |
